October 01, 2016 6:49 AM ET


Company Overview of PLx Pharma Inc.

Company Overview

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing oral drugs for cardiovascular disease, as well as pain and inflammation for the prescription and over-the-counter markets in the United States. The company’s products include PL2200 Aspirin 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute GI side effects while providing antiplatelet effectiveness for cardiovascular disease prevention; and PL2200 Aspirin 81 mg that is in late-stage development. PLx Pharma Inc. was founded in 2002 and is headquartered in Houston, Texas.

8285 El Rio

Suite 130

Houston, TX 77054

United States

Founded in 2002

6 Employees





Key Executives for PLx Pharma Inc.

Chief Executive Officer, President and Director
Age: 56
Executive Chairman
Age: 62
Founder, Senior Advisor and Director
Age: 63
Scientific Founder and Chairman of Scientific Advisory Board
Acting Chief Financial Officer and Director
Age: 54
Compensation as of Fiscal Year 2016.

PLx Pharma Inc. Key Developments

PLx Pharma Inc. Announces Management Changes

PLx Pharma Inc. announced that Natasha Giordano has been appointed as President and Chief Executive Officer, and as a member of the company's Board of Directors, effective January 1, 2016. Ms. Giordano will be replacing Ronald R. Zimmerman, who will remain on the Board of Directors and continue in a role as Founder and Senior Advisor providing support for pre-commercialization activities, regulatory affairs, and business development. Ms. Giordano joins PLx Pharma with over 25 years’ experience as an accomplished and versatile senior leader successfully achieving enterprise-wide strategic and financial goals across industries with a focus on Pharmaceuticals and Healthcare Technologies. Ms. Giordano is proficient in building commercialization plans including developing sales forces, raising capital, and is a skilled turnaround specialist known for her novel risk mitigation approaches. Prior to joining PLx Pharma, Ms. Giordano was President and CEO of Clear Point Learning.

PLx Pharma Mulls Acquisitions

PLx Pharma Inc. is seeking acquisitions. The company intends to use net proceeds from its Initial Public Offer for acquisitions, it said in its filing on stock exchange.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
February 23, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PLx Pharma Inc., please visit www.plxpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.